Essential Reads: Recognizing Postpartum Psychosis Because postpartum psychosis is a relatively rare event, we do not have as much information on this illness as we have on postpartum depression. In addition, most of the literature we have on postpartum psychosis is not new. A few years back, the American Journal of Psychiatry published an excellent… Read More »
In Brief: Postpartum Depression Common in COVID-Positive Women Separated from Their Newborns Soon after the COVID-19 pandemic emerged, the American Academy of Pediatrics recommended temporarily separating newborns from mothers who tested positive for COVID-19 immediately after delivery. In a retrospective cohort study of 224 new mothers delivering at a New York hospital between March 18… Read More »
There is evidence in non-perinatal populations that human coronaviruses can be neurotropic and that virus infection may increase vulnerability to neuropsychiatric illness, including depression, anxiety, psychosis and delirium. Based on this finding, researchers have speculated that there may be an association between contracting COVID-19 and developing a postpartum psychiatric illness. This hypothesis has been preliminarily… Read More »
By Amy Norton HealthDay Reporter THURSDAY, Oct. 29, 2020 (HealthDay News) — Many women have depression symptoms after giving birth, but for some postpartum depression hangs on for years, a U.S. government study finds. Of nearly 4,900 new mothers researchers followed, one-quarter had depression symptoms at some point in their child’s first three years. And… Read More »
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been finishing up its Phase 3 trials. Like brexanolone, SAGE-217 is a neuroactive steroid, an analogue of allopregnanolone which is a… Read More »